Sectors

Health Care

The preeminent health care destination for capital markets advice and research coverage

Research capabilities for
the
Health Care sector

Cowen’s health care equity research is agenda-setting, and our footprint is among the largest. Our analysts’ work has been validated in third-party polls, such as Institutional Investor’s All-America Research Team, the Greenwich Associates poll, and Starmine. In addition to company-specific research, our team publishes over 17,000 pages of industry research annually. Publications such as Biotechnology Quarterly, Pharmaceutical Industry Pulse, Specialty Pharmaceutical Pulse, Therapeutic Categories Outlook, Life Science Tool Kit, and Diagnostics Kit have become legend among investors.

 

Similarly, our Ahead Of The Curve ™ reports are at the center of conversation.

Our annual Health Care Conference remains one of Wall Street’s most highly regarded, and is the epicenter of discussion for corporate executives, institutional investors, venture capitalists, and health care professionals.

Learn more about our research expertise

Team

General Contact

Robert Fagin
Head of Research
D 646 562 1310
robert.fagin@cowen.com

Stephen E. Reilly
Co-director of Research
D 617 946 3901
steve.reilly@cowen.com

Lisa Thomas
Associate Director of Research
D 646 562 1388
lisa.thomas@cowen.com

Investment Banking capabilities for
the
Health Care sector

Cowen’s health care investment banking Group combines the global resources and full service product capabilities of a leading financial institution with the focus and commitment of a specialty investment banking firm.

Focused on financings and financial advisory for life sciences, medical technology and health care services companies our health care team have developed industry contacts which are leveraged to result in flawless execution and long-term client support.

Learn more about our investment banking expertise

 

Latest Transactions

  • Avita intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund the marketing and sales effort to support U.S. market launch of the RECELL System
  • Rocket Pharmaceuticals intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund the continued development of the pipeline of gene therapies for rare diseases, enhancements to in-house manufacturing efforts, potential in-license, acquisition or investment in complementary businesses or products, and intends to use the remainder for general working capital and administrative purposes.
  • Acadia intends to use the net proceeds of this offering to fund ongoing commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin and trofinetide, and for general corporate purposes, including working capital.

Team

General Contact

George Milstein
Head of Health Care
D 415 646 7394
george.milstein@cowen.com